London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Article in Express with reference to Apollon Formularies
https://www.express.co.uk/life-style/health/1584045/prostate-cancer-treatment-medicinal-cannabis
Daily express - yes it's publicity but an express article carries as much credibility as the graffiti on the wall of a public urinal.
It's data that's needed. Not 3D cell culture data, data from real life people showing that APO products make a real difference to their projected outcomes. APO are on the case but it will be some time yet before we hear. Meantime the 2.8p offer price after several months is dipping to 2.6p from time to time.
I kinda think this Co. may have floated a bit early. The repetition of the same twitter information time after time doesn't inspire confidence.
Well....52.72% of the shares are held by the directors and the last placing was at 5.00p, so I don't think it will take very long to move the price up once revenue enhancing news lands.
You must have missed this announcement as well:
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange and focused on the treatment of various cancer conditions using its proprietary medical cannabis formulations, is pleased to announce it is advancing an application to join the OTCQB Market ("OTCQB") in the United States. Apollon's Ordinary Shares will continue to trade on the Aquis Stock Exchange under the symbol APOL.
The Company decided to undertake this application for a second trading platform for its shares at the request of several US based investors and believes that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity.
Apollon is also pleased to announce that it is exploring other possible up-listing options on local and international exchanges to increase investor access. The Company will maintain its existing AQSE listing, in addition to any additional up-listing it may undertake.
The Company believes that, due to the growth it has seen both in terms of the build out of its facilities and the increase in patient enquiries, moving to a more well-established exchange will provide easier trading access for institutional investors and improve liquidity for all shareholders.